A Cohort Study of First-line Treatment of Patients With Unresectable Advanced (Stage IIIB), Metastatic (Stage IV) or Recurrent Non Squamous Non-small Cell Lung Cancer (NSCLC), Starting a Treatment With Bevacizumab (Avastin) in Combination With Chemotherapy.

Trial Profile

A Cohort Study of First-line Treatment of Patients With Unresectable Advanced (Stage IIIB), Metastatic (Stage IV) or Recurrent Non Squamous Non-small Cell Lung Cancer (NSCLC), Starting a Treatment With Bevacizumab (Avastin) in Combination With Chemotherapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 May 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Antineoplastics
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 01 Nov 2012 Planned end date changed from 1 Jan 2014 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 01 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 14 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top